Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
28.33
-0.20 (-0.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
Next >
NASDAQ:GMAB is not too expensive for the growth it is showing.
April 11, 2024
Via
Chartmill
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
April 08, 2024
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
April 03, 2024
Genmab is buying a privately held company focused on antibody drug conjugates.
Via
Investor's Business Daily
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
March 28, 2024
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.
Via
Chartmill
Analyst Ratings For Genmab
March 26, 2024
Via
Benzinga
4 Analysts Assess Genmab: What You Need To Know
February 20, 2024
Via
Benzinga
Earnings Outlook For Genmab
February 13, 2024
Via
Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
February 08, 2024
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
March 21, 2024
For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.
Via
Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
March 05, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
February 29, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
February 08, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Genmab
January 29, 2024
Via
Benzinga
What's Going On With Danish Healthcare Firm Genmab Stock?
January 23, 2024
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
January 18, 2024
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via
Chartmill
9 Analysts Have This to Say About Genmab
November 28, 2023
Via
Benzinga
NASDAQ:GMAB is not too expensive for the growth it is showing.
November 10, 2023
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via
Chartmill
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
December 26, 2023
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via
Chartmill
Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 12, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
In the world of growth stocks, NASDAQ:GMAB shines as a value proposition.
December 05, 2023
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).
Via
Chartmill
7 Must-Buy Stocks That Are on Ridiculous Discount Now
November 13, 2023
With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale.
Via
InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Analyst Expectations for Genmab's Future
November 08, 2023
Via
Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
November 01, 2023
GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
What 13 Analyst Ratings Have To Say About Genmab
October 13, 2023
Via
Benzinga
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
October 20, 2023
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 18, 2023
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Expert Ratings for Genmab
September 26, 2023
Via
Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
September 26, 2023
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.